Trade Name(s)

  • Zioptan

Ther. Class.

ocular hypotensive agent

Pharm. Class.



Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic Effect(s):

↓ intraocular pressure.


Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.

Distribution: Unknown.

Metabolism and Excretion: Further metabolized and eliminated.

Half-life: Unknown.

TIME/ACTION PROFILE (↓ in intraocular pressure)

Ophthwithin 2–4 hr12 hr24 hr


Contraindicated in:

  • Pedi:  Avoid use in children due to unknown safety of chronic ↑ pigmentation.

Use Cautiously in:

  • Aphakia, pseudoaphakia with a torn posterior lens capsule
  • Known risk factors for macular edema
  • OB:  Women with child-bearing potential should practice adequate contraception
  • Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

EENT: conjunctival hyperemia, blurred vision, cataract, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation, permanent iris pigmentation

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Note noted.


Ophth:  (Adults): One drop once daily (into conjunctival sac) in the evening into affected eye(s).


Ophthalmic solution : 0.0015% in 0.3 mL single-use containers


  • Measure intraocular pressure periodically during therapy.


  • Ophth:  

    Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.

    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the  Patient Information Leaflet  prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

Reduction of intraocular pressure.